Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Frequency of KRAS p.Gly12Cys Mutation in Brazilian Patients With Lung Cancer

2021; Lippincott Williams & Wilkins; Issue: 7 Linguagem: Inglês

10.1200/go.20.00615

2687-8941

Rodrigo de Oliveira Cavagna, Flávia Escremim de Paula, Débora Sant'Anna, Iara Viana Vidigal Santana, Vinícius Duval da Silva, Eduardo Caetano Albino da Silva, Carlos E. Bacchi, José Elias Miziara, Josiane Mourão Dias, Pedro De Marchi, Letícia Ferro Leal, Rui Manuel Reis,

Lung Cancer Research Studies

Recently, the agents AMG-510 (sotorasib, Amgen, Thousand Oaks, CA) and MRTX849 (adagrasib, Mirati Therapeutics, San Diego, CA) were developed to target the KRAS p.Gly12Cys mutation. 24,255][26] In a phase I study, 32.2% (19 out of 59) of sotorasib-treated patients presented with objective response, and 88.1% (52 out of 59) presented with the disease control. 26In a phase I and II study, 94% (17 out of 18) adagrasib-treated lung patients presented with disease control, and objective response was not yet available (KRYSTAL-1 study; ClinicalTrials.govidentifier: NCT03785249). 25e frequency of KRAS p.Gly12Cys in admixture NSCLC populations remains scarce.Herein, we report the frequency of the KRAS p.Gly12Cys mutation in a series of 844 Brazilian NSCLC cases, followed by the data gathered from Brazil's previously reported studies.